|
|
|
|
|
Legal status
Patent not validated
| (51) | INT.CL. | A61K 38/17 | (2006.01) |
| A61K 39/395 | (2006.01) | ||
| C07K 19/00 | (2006.01) | ||
| C07K 16/28 | (2006.01) | ||
| A61P 37/00 | (2006.01) |
| (11) | Number of the document | 2233149 |
| (13) | Kind of document | T |
| (96) | European patent application number | 10167232.7 |
| Date of filing the European patent application | 2008-10-16 | |
| (97) | Date of publication of the European application | 2010-09-29 |
| (45) | Date of publication and mention of the grant of the patent | 2016-02-10 |
| (46) | Date of publication of the claims translation |
| (30) | Number | Date | Country code |
| 980331 P | 2007-10-16 | US |
| (72) |
Broly, Herve, FR
Ponce Jr., Rafael A., US
Graffner, Hans Otto Lennart, SE
Peano, Sergio, IT
|
| (73) |
ARES TRADING S.A.,
Zone Industrielle de l`Ouriettaz, 1170 Aubonne,
CH
ZymoGenetics, Inc., 1201 Eastlake Avenue East, Seattle, Washington 98102, US |
| (54) | Combination of transmembrane activator and calcium modulator and cyclophilin ligand interactor (TACI) and anti-CD20 agents for treatment of autoimmune disease |
| Combination of transmembrane activator and calcium modulator and cyclophilin ligand interactor (TACI) and anti-CD20 agents for treatment of autoimmune disease |